15.09.2021 10:49 Uhr in Wissenschaft & Forschung und in Gesundheit & Wellness von OrganoTherapeutics
Jens Schwamborn
740x493 Pixel - Dateigröße: 72,63 Kb
Jens Schwamborn and Javier Jarazo founded Organo Therapeutics as a spin-off and are breeding since 2019 so-called mini-brains specifically for the midbrain to aid in the development of new drugs for Parkinson's disease. Jens Schwamborn and Javier Jarazo have been awarded the SLAS New Product Award in January 2021 and in April 2021 with the BioVaria Startup Award, just shortly after the Luxembourgish Ministry of Economy confirmed support for Organo Therapeutics project "Drug repurposing to target SARS-CoV-2 brain infection”.
... weiter lesen Quelle
Pressefach abonnieren
via RSS-Feed abonnieren
via E-Mail abonnieren
Pressekontakt
Herr Jens Schwamborn
OrganoTherapeutics
Avenue des Hauts-Fourneaux 6A
4365 Esch-sur-Alzette
Luxemburg
Drucken
Weiterempfehlen
PDF
Schlagworte
OrganoTherapeutics
Avenue des Hauts-Fourneaux 6A
4365 Esch-sur-Alzette
Luxemburg
jens-schwamborn
jens-c.-schwamborn
prof.-jens-schwamborn
jens-christian-schwamborn
prof.-dr.-jens-schwamborn
jens-schamborn-retraction
Permanentlinks
https://www.prmaximus.de/136961https://www.prmaximus.de/pressefach/organotherapeutics-pressefach.html
Die Pressemeldung "Jens Schwamborn Interview: Developing drugs for Parkinson's with mini-brains" unterliegt dem Urheberrecht.
Jegliche Verwendung dieses Textes, auch auszugsweise, erfordert die vorherige schriftliche Erlaubnis des Autors.
Autor der Pressemeldung "Jens Schwamborn Interview: Developing drugs for Parkinson's with mini-brains" ist OrganoTherapeutics, vertreten durch Jens Schwamborn.